Doppler Ultrasound in Characterization of Superficial Soft Tissue Masses
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03171857 |
|
Recruitment Status : Unknown
Verified May 2017 by Andrew Samir, Assiut University.
Recruitment status was: Not yet recruiting
First Posted : May 31, 2017
Last Update Posted : May 31, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease |
|---|
| Mass of Soft Tissue |
There are many examples for these benign superficial soft tissue lesions as lipoma, ganglion, Baker's cyst, giant cell tumor, lymphangioma, hernia, abscess, epidermoid cyst, hematoma, muscle rupture, glomus tumor, fibromatosis, lymphadenitis hemangioma, exostosis, fibroma, neurofibroma and schwannoma. Malignant lesions also could be seen as lymphoma, metastasis, osteogenic sarcoma, liposarcoma , leiomyosarcoma, rhabdomyosarcoma and synovial sarcoma.
Nowadays, High resolution ultrasound has a high sensitivity in detecting superficial soft tissue masses through the grey-scale grading that compose an image range from pure black at the weakest intensity to pure white at the strongest that can be used to evaluate its structure, some aspects of its function and to determine the nature of a mass lesion (cystic or solid) and with Doppler ultrasound which is an excellent imaging modality to determine the vascularity of superficial soft tissue masses that can be characterized in terms of their echogenicity, margin, shape, composition, acoustic transmission, size, the grading of color Doppler ultrasound , and resistive index in spectral Doppler as spectral Doppler will be applied in lesions with positive color flow signals.
| Study Type : | Observational |
| Estimated Enrollment : | 40 participants |
| Observational Model: | Case-Only |
| Time Perspective: | Prospective |
| Official Title: | Role of Doppler Ultrasound in Evaluation of Superficial Soft Tissue Masses |
| Estimated Study Start Date : | June 1, 2017 |
| Estimated Primary Completion Date : | June 1, 2019 |
| Estimated Study Completion Date : | September 1, 2019 |
- Patients diagnosed as superficial soft tissue lesions by doppler ultrasound. [ Time Frame: 2 years ]Effectiveness of Doppler ultrasound in evaluation of superficial soft tissue masses in comparison with histopathological data of these lesions.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | Child, Adult, Older Adult |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Patients in different age groups with superficial soft tissue lesions
Exclusion Criteria:
- If the patient undergo previous operations at the same mass that could change the criteria of that mass or if the mass is recurrent at the same site.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03171857
| Contact: Hasan Ibrahim Megalli, Professor | 01006209584 | hasanibrahim48@yahoo.com | |
| Contact: Abeer Hussein Ali, Lecturer | 01007078382 | abeeryaa@yahoo.com |
| Responsible Party: | Andrew Samir, principal investigator, Assiut University |
| ClinicalTrials.gov Identifier: | NCT03171857 |
| Other Study ID Numbers: |
DUSSSTM |
| First Posted: | May 31, 2017 Key Record Dates |
| Last Update Posted: | May 31, 2017 |
| Last Verified: | May 2017 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |

